Wednesday , October 14 2015

Need comprehensive information on the leading diabetes therapeutic options? It’s at your fingertips in our Therapy Centers.

Featured Therapies:

GLP-1 Agonist

Enter our Insulin Advice Contest! Winning entry receives a $100 Amazon gift card.

From the Editor

October, 2015

  • 12 October


    Editor’s Note We all have heard about the value of the  Mediterranean Diet for our CV patients. In addition clinicians often advise patients to use this food plan to reduce LDL, weight and glucose levels. What is it about these food choices that cause improvements in CV outcomes? This week our ...

    Read More »

Latest Articles

October, 2015

Test Your Knowledge

Question #802

A 54-year old male presents to your office for an initial visit. His past medical history is significant for hypertension, hypertriglyceridemia and acute pancreatitis. His current lab results show an A1C 9.1%, which is confirmed on a repeat lab. You would like to start him on an antihyperglycemic treatment regimen. Which of the following two-drug combinations is contraindicated for this patient?



Answer:  D. Metformin + a GLP-1 receptor agonist

Given this patient's A1C, initiating a 2-drug combination therapy would be an appropriate choice. The incretin-based drugs (GLP-1 receptor agonist and DPP-4 inhibitors) are contraindicated if there is a history of pancreatitis as they have been linked to reports of acute pancreatitis, although their possible role increasing the risk of pancreatitis is not clear. The GLP-1 receptor agonists are glucose dependent and work at the pancreatic level to stimulate insulin secretion and suppress glucagon production. DPP-4 inhibitors inhibit DDP-4 (DDP-4 inactivates the incretins), leading to an increase in active incretin levels.


Inzucchi S, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6):1364-1379.


More Articles

October, 2015